İnvaziv lobüler meme karsinomunun klinik özellikleri ve sağkalim sonuçları

Year 2024, Volume: 15 Issue: 2, 190 - 197, 01.07.2024

Mukaddes Yılmaz Eda Erdiş Mahmut Uçar Birsen Yücel

https://doi.org/10.18663/tjcl.1458189

Abstract

Amaç: Bu çalışmada kliniğimize başvuran invaziv lobuler meme kanseri tanılı hastaların klinik özellikleri ve sağkalım sonuçlarını araştırdık.
Gereç ve Yöntemler: Cumhuriyet Üniversitesi Onkoloji Merkezi'ne 2007-2019 yılları arasında başvuranlardan invazif lobüler karsinom tanısı alan hastalar retrospektif olarak incelendi..
Bulgular: Çalışmada 1166 invaziv meme kanseri kadın hastanın dosyası incelenmiş ve bunlardan 64’ünün (5,5%) invaziv lobular meme kanseri alt tipinde olduğu tesbit edilmiştir. Tanıda 30 (47%) hastanın evre I-II, 31 (48%) hastanın evre III ve 3 (5%) hastanın ise evre IV olduğu tesbit edilmiştir. Histopatolojik değerlendirmelere göre hastaların 60’nda (94%) estrogen reseptörü (ER) pozitif, 53’ünde (83%) progesterone reseptörü (PR) pozitif, 6’sında (9%) HER2-pozitif olarak tesbit edildi. Yapılan tedaviler değerlendirildiğinde 48 (75%) hastaya modifiye radikal mastektomi, 15 (23%) hastaya meme koruyucu cerrahi uygulanmıştır ve 54 (84%) hastaya adjuvant kemoterapi, 55 (86%) hastaya hormonterapi ve 44 (69%) hastaya radyoterapi verilmiştir. Takipte 14 (22%) hastada metastaz tesbit edilmiş olup metastaza kadar geçen süre medyan 38 (6-76) aydı. Hastaların 5 yıllık genel sağkalım ve event-free survival sırasıyla 80% ve 73%’tü.
Sonuçlar: Çalışmamızda invaziv lobuler karsinomlu hastalar çoğunluğunu postmenopozal kadınların oluşturduğu, daha çok ileri evrelerde tanı alan, histopatolojik olarak hormon reseptörü pozitifliği yaygın görülen meme kanseri alt tipini temsil etmektedir.

Keywords

meme kanseri, invaziv lobuler karsinom, klinik özellikler, sağkalım

Ethical Statement

Araştırmanın etik onayı Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Etik Kurulu'ndan alınmıştır (Tarih: 21.12.2023, No: 2023-12/19)

Supporting Institution

yok

Clinical features and survival outcomes of invasive lobular breast carcinoma

Abstract

Aim: In this study, we investigated the clinical features and survival outcomes of patients diagnosed with invasive lobular breast cancer who presented to our clinic.
Material and Methods: Patients diagnosed with invasive lobular carcinoma who applied to Cumhuriyet University Oncology Center between 2007 and 2019 were examined retrospectively.
Results: In the study, the files of 1166 female patients with invasive breast cancer were reviewed, and it was determined that 64 of them (5.5%) had the invasive lobular carcinoma subtype. At diagnosis, 30 patients (47%) were in stage I-II, 31 patients (48%) were in stage III, and 3 patients (5%) were in stage IV. According to histopathological evaluations, 60 patients (94%) were found to be estrogen receptor (ER) positive, 53 patients (83%) were progesterone receptor (PR) positive, and 6 patients (9%) were HER2-positive. Regarding the treatments administered, 48 patients (75%) underwent modified radical mastectomy, 15 patients (23%) underwent breast-conserving surgery, 54 patients (84%) received adjuvant chemotherapy, 55 patients (86%) received hormone therapy, and 44 patients (69%) received radiotherapy. During follow-up, metastasis was detected in 14 patients (22%), with a median time to metastasis of 38 months (range 6-76 months). The 5-year overall survival and disease-free survival were 80% and 73%, respectively.
Conclusion: In our study, invasive lobular breast carcinoma was determined to be a common subtype of breast cancer, the majority of which are postmenopausal women, are diagnosed at advanced stages, and histopathologically hormone receptor positivity is common.

Keywords

breast cancer, invasive lobular carcinoma, clinical features, survival

References

• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 17;406(6797):747-52. https://doi.org/10.1038/35021093.
• Thomas M, Kelly ED, Abraham J, Kruse M. Invasive lobular breast cancer: a review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol. 2019;46(2):121-132. https://doi.org/10.1053/j.seminoncol.2019.03.002.
• Oesterreich S, Nasrazadani A, Zou J, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114(11):1511-1522. https://doi.org/10.1093/jnci/djac157.
• García-Fernández A, Lain JM, Chabrera C, et al. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival. Breast J. 21(5):533-7. doi: 10.1111/tbj.12455. Epub 2015 Jul 17.
• Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994 15;73(6):1673-7. https://doi.org/10.1002/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co;2-b.
• Raap M, Antonopoulos W, Dammrich M, et al. High frequency of lobular breast cancer in distant metastases to the orbit. Cancer Med. 2015 Jan;4(1):104-11. https://doi.org/10.1002/cam4.331.
• Mathew A, Rajagopal PS, Villgran V, et al. Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast. Geburtshilfe Frauenheilkd. 2017;77(6):660-666. doi:10.1055/s-0043-109374.
• Fortunato L, Mascaro A, Poccia I, et al. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period. Ann Surg Oncol. 2012 Apr;19(4):1107-14. doi: 10.1245/s10434-011-1907-9. Epub 2011 Sep 13.
• Adachi Y, Ishiguro J, Kotani H, et al. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer. 2016;16:248. doi:10.1186/s12885-016-2275-4.
• Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008; 26(18):3006-3014. doi:10.1200/J Clin Oncol.2007.14.9336.
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775.
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529.
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47. doi: 10.1093/annonc/mdr304.
• Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002;11(7):601-7.
• Findlay-Shirras LJ, Lima I, Smith G, Clemons M, Arnaout A. Population Trends in Lobular Carcinoma of the Breast: The Ontario Experience. Ann Surg Oncol. 2020;27(12):4711-4719. doi: 10.1245/s10434-020-08895-8.
• Kee GJ, Tan RY, Rehena S, et al. Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience. World J Clin Oncol. 2020:24;11(5):283-293. doi: 10.5306/wjco.v11.i5.283.
• Chamalidou C, Fohlin H, Albertsson P, et a. Swedish western and south-eastern breast cancer groups. Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. Breast. 2021;59:294-300. doi: 10.1016/j.breast.2021.07.011. Epub 2021 Jul 22.